GlassScriptPhysician profile
Candace A Elliott
NPI 1700853728
$3,627.52
in general payments reported to CMS, 2019-2025
19 companies · $918 in 2025
The $918 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $361 · 2022: $888 · 2023: $671 · 2024: $790 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,378 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,377.74 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $597.05 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Edwards Lifesciences Corporation | $534.80 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbott Laboratories | $290.74 | 2023-2025 | Infinity, Alinity |
| Abbvie INC. | $248.79 | 2021-2023 | |
| Novo Nordisk INC | $223.21 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $221.96 | 2022-2024 | Dupixent |
| Neurocrine Biosciences, INC. | $173.88 | 2022 | |
| Madrigal Pharmaceuticals | $145.18 | 2025 | Rezdiffra |
| Alnylam Pharmaceuticals INC. | $143.72 | 2025 | Onpattro |
| Silk Road Medical, INC. | $133.34 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Boston Scientific Corporation | $125.00 | 2021 | |
| Shield Therapeutics INC | $123.78 | 2023 | Accrufer |
| Melinta Therapeutics, LLC | $121.95 | 2022 | |
| Myovant Sciences INC. | $121.32 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $109.93 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $97.46 | 2024 | Intellis Adaptivestim |
| Scynexis, INC. | $83.33 | 2022 | |
| Sanofi-Aventis U.S. LLC | $81.98 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $50.10 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candace Elliott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.